scholarly journals Clinical Efficacy of Neurointerventional Catheter Thrombolysis for Cerebral Infarction

2019 ◽  
Vol 3 (6) ◽  
Author(s):  
Qiangyuan Tian ◽  
Guangchao Zhu ◽  
Shugang Dong
Keyword(s):  
Cerebral Infarction ◽  
Clinical Efficacy ◽  
Neurological Deficit ◽  
Arterial Catheter ◽  
Control Group ◽  
Observation Group ◽  
Nihss Score ◽  
Before And After ◽  
Catheter Thrombolysis ◽  
Better Than

Objective: To analyze the clinical efficacy of neurointerventional catheter thrombolysis for cerebral infarction. METHODS: A total of 56 patients with cerebral infarction admitted to our hospital from April 2018 to June 2019 were enrolled for the experimental study. Two different treatments were applied to patients, and patients were divided into observation groups and controls according to different treatment methods. After grouped into two groups the control group was treated with intravenous thrombolysis. The observation group was treated with neurointerventional arterial catheter thrombolysis. The treatment effect, NIHSS score and BI index, neurological deficit score before and after treatment, and coagulation index were compared between the two groups. RESULTS: The therapeutic effect of the observation group (92.86%) was significantly different from that of the control group (67.86%), and the observation group was higher than the control group. The data of the observation group in the NIHSS score and the BI index were 5.42±1.77 and 95.64±2.15, respectively, which were better than the control group. The neurological deficit scores of the observation group before and after treatment were 19.88±6.24 and 9.14±5.81, respectively. After treatment, the difference was significant compared with the control group, p<0.05. The coagulation indexes of the observation group in FIB, PT, TT, etc. were respectively 3.68±1.04, 11.46±1.62, 15.37±2.46, all were better than the control group (2.13±0.47, 13.72±2.72, 19.85±2.62), P<0.05. Conclusion: the clinical efficacy of neurointerventional arterial catheter thrombolysis for cerebral infarction is significant, it can effectively promote the recovery of various functional conditions of patients with cerebral infarction, which is worthy of further application and promotion.

scholarly journals Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction

2019 ◽  
Vol 35 (4) ◽  
Author(s):  
Xiaoying Liu ◽  
Shengli Rao ◽  
Jiajia Wang
Keyword(s):  
Cerebral Infarction ◽  
Conventional Treatment ◽  
Mild Hypothermia ◽  
Intravenous Thrombolysis ◽  
Acute Cerebral Infarction ◽  
Control Group ◽  
Observation Group ◽  
Nihss Score ◽  
Time Points ◽  
Before And After

Objective: To investigate the efficacy of recombinant tissue plasminogen activator (rt-PA) intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction. Methods: One hundred and thirty-two patients with acute cerebral infarction who were admitted to our hospital were selected and grouped into a control group and an observation group, 66 each group. Patients in the control group were given conventional treatment in combination with local mild hypothermia therapy, and patients in the observation group were given rt-PA intravenous thrombolysis on the basis of conventional treatment and local mild hypothermia therapy. National institute of health stroke scale (NIHSS) score and intracranial pressure (ICP) of the two groups before and after treatment was recorded. The efficacy of the two groups was evaluated. The modified Rankin scale (MRS) score was followed up for three months. The blood samples of the patients were collected before and after thrombolysis. Superoxide dismutase (SOD) and malondialdehyde (MDA) levels in the plasma were detected. Results: The NIHSS score of the two groups decreased in the 1st, 3rd and 7th day after treatment compared to before treatment (p<0.05), but the NIHSS score of the two groups had no significant difference at different time points after treatment (p>0.05). The ICP of the two groups decreased in the 1st, 3rd and 7th day after treatment compared to before treatment (p<0.05), and the decrease of ICP of the observation group was more significant than that of the control group at the same time point (1st, 3rd and 7th day after treatment) (p<0.05). The clinical efficacy of the observation group was higher than that of the control group after treatment, and the difference was statistically significant (p<0.05). The MDA concentration of both groups decreased at different time points after treatment (p<0.05), but the SOD concentration increased (p<0.05). The MDA concentration of the observation group was lower than that of the control group at different time points after treatment (p<0.05), and the SOD concentration of the observation group was higher than that of the control group (p<0.05). Conclusion: rt-PA intravenous thrombolysis in combination with mild hypothermia therapy has significant efficacy in the treatment of acute cerebral infarction. It can effectively relieve neurological function. Its action mechanism may be realized by relieving oxidative stress response. doi: https://doi.org/10.12669/pjms.35.4.311 How to cite this:Liu X, Rao S, Wang J. Intravenous thrombolysis in combination with mild hypothermia therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2019;35(4):1161-1166. doi: https://doi.org/10.12669/pjms.35.4.311 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction

2020 ◽  
Vol 36 (4) ◽  
Author(s):  
Xuewen Wo ◽  
Jinyan Han ◽  
Jiajia Wang ◽  
Xinmin Wang ◽  
Xiaoying Liu ◽  
...  
Keyword(s):  
Plasma Level ◽  
Cerebral Infarction ◽  
Antiplatelet Therapy ◽  
Adverse Reactions ◽  
Dual Antiplatelet Therapy ◽  
Acute Cerebral Infarction ◽  
Control Group ◽  
Observation Group ◽  
Significant Difference ◽  
Better Than

Objective: To observe the clinical efficacy of sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of elderly patients with acute cerebral infarction (ACI). Methods: One hundred and twenty-two elderly patients with ACI who were admitted to the department of neurology of our hospital at May 2016-August 2018 were selected grouped into a control group and an observation group by random number table method, 61 in each group. On the basis of conventional treatment, the patients in the control group were given dual antiplatelet therapy (aspirin enteric-coated tablets + clopidogrel bisulfate tablets), while the patients in the observation group were given sequential butylphthalide therapy on the basis of the control group. The clinical effects of the two groups were compared after four weeks of treatment, and the changes of National Institutes of Health Stroke Scale (NIHSS), ADL score, plasma 3-mercaptopyruvate sulphurtransferase (3-MST) and Amyloid β42 (Aβ42) levels and the occurrence of adverse reactions during treatment were recorded. Results: The clinical efficacy of the observation group was better than that of the control group (P<0.05). There was no significant difference in NIHSS and ADL scores between the two groups before treatment (P>0.05). After treatment, the NIHSS and ADL scores of the observation group were better than those of the control group (P<0.05). There was no significant difference in plasma levels of 3-MST and AB42 between the two groups before treatment (P>0.05). The level of plasma 3-MST in the observation group was higher than that in the control group, and the level of plasma Aβ42 was lower than that in the control group (P<0.05). No serious adverse reactions occurred during the treatment period in both groups. Conclusion: Butylphthalide sequential therapy combined with dual antiplatelet therapy is effective in the treatment of elderly ACI. It can effectively improve the plasma level of 3-MST and decrease the plasma level of Aβ42, which is conducive to improving the living ability and neurological function of patients and has high safety. doi: https://doi.org/10.12669/pjms.36.4.1831 How to cite this:Wo X, Han J, Wang J, Wang X, Liu X, Wang Z. Sequential butylphthalide therapy combined with dual antiplatelet therapy in the treatment of acute cerebral infarction. Pak J Med Sci. 2020;36(4):---------. doi: https://doi.org/10.12669/pjms.36.4.1831 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

scholarly journals Study on the clinical efficacy and mechanism of octreotide combined with thrombin in patients with liver

1970 ◽  
Vol 1 (1) ◽  
Author(s):  
Zhang Xiuqin
Keyword(s):  
Liver Cirrhosis ◽  
Liver Function ◽  
Clinical Efficacy ◽  
Effective Rate ◽  
Control Group ◽  
Observation Group ◽  
Before And After ◽  
Octreotide Treatment ◽  
The Difference ◽  
Treatment Observation

Objective: To observe the clinical efficacy of octreotide and thrombin in the treatment of patients with liver cirrhosis, and to explore the mechanism of octreotide and thrombin. Methods: 53 patients with cirrhosis were randomly divided into control group and observation group from January 2014 to January 2016. The control group of 26 patients, given octreotide treatment. Observation group of 27 cases, given octreotide and thrombin combination therapy. Comparison of two groups of patients with clinical efficacy and changes in liver function before and after treatment. Results: The effective rate (88.89%) in the observation group was significantly higher than that in the control group (65.38%), the difference was statistically significant (p < 0.05). Before treatment, the difference of liver function between the two groups was not statistically significant (p > 0.05). After treatment, the liver function indexes of the two groups were improved, and the observation group was superior to the control group, the difference was statistically significant (p < 0.05).

scholarly journals Edaravone Combined with Clopidogrel Is Beneficial to Improve Efficacy, Neurological Impairment, and Life Function in Acute Cerebral Infarction Patients

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Liao Wu ◽  
Ying Sun ◽  
Guihua Ni ◽  
Bo Sun ◽  
Xiaoyu Ni ◽  
...  
Keyword(s):  
Cerebral Infarction ◽  
Neurological Deficit ◽  
Daily Living ◽  
Adverse Reactions ◽  
Neurological Impairment ◽  
Acute Cerebral Infarction ◽  
Control Group ◽  
Nihss Score ◽  
Cerebral Hemodynamic ◽  
Life Function

Objective. This research aimed at investigating the efficacy of edaravone combined with clopidogrel on acute cerebral infarction (ACI) and its influence on the neurological deficit and life function. Methods. Totally, 154 ACI cases were included and then divided into the control group (CG) (n = 71) and research group (RG) (n = 83) according to the treatment methods. Patients in the CG were treated with clopidogrel alone, and those in the RG were under edaravone-clopidogrel combination therapy. The efficacy, adverse reactions, NIHSS score, cerebral hemodynamic indexes, and Fugl-Meyer scale (FMA) and Barthel index (BI) of activities of daily living (ADL) scores were observed. Results. Compared with before treatment, the symptoms of both groups were improved after treatment: the NIHSS scores decreased, FMA and ADL scores increased, and cerebral hemodynamic indexes were improved. Compared with the CG, the efficacy and cerebral hemodynamic indexes of the RG were better, the adverse reactions were equivalent, the NIHSS score was lower, and the ADL and FMA scores were higher. Conclusion. Edaravone combined with clopidogrel can effectively treat ACI and improve the neurological deficit and life function of patients.

scholarly journals The Efficacy of Tripterygium Glycosides Combined with LMWH in Treatment of HSPN in Children

2021 ◽  
Vol 2021 ◽  
pp. 1-6
Author(s):  
Yan Jin ◽  
Yanzheng Wang ◽  
Sai Wang ◽  
Qiongqiong Zhao ◽  
Donghua Zhang ◽  
...  
Keyword(s):  
Clinical Efficacy ◽  
Clinical Symptoms ◽  
Effective Rate ◽  
Control Group ◽  
Clinical Effects ◽  
Observation Group ◽  
Significant Difference ◽  
Before And After ◽  
Qilu Hospital ◽  
Tripterygium Glycosides

Objective. This study aimed to explore the clinical efficacy and relevant mechanism of Tripterygium glycosides combined with low molecular weight heparin calcium (LMWH) in the treatment of Henoch–Schönlein purpura nephritis (HSPN) in children. Methods. 64 cases of children patients with HSPN treated at Qilu Hospital (Qingdao) from January 2015 to May 2020 were selected and randomly divided into the control group and the observation group and 32 cases in each group. Conventional medical treatment was applied in the two groups, besides which the control group was given LMWH while the observation group was given Tripterygium glycosides based on the control group. The clinical efficacy and the indexes of clinical symptoms of the two groups were compared. Immune globulin level, fibrinogen content (FIB), prothrombin time (PT), platelet level (PLT), and activated partial thromboplastin time (APTT) level of the two groups were compared before and after the treatment. Results. The total effective rate in the observation group was significantly higher than that of the control group, and the recurrence rate in the observation group was lower than that in the control group. After treatment, urine red blood cell count and 24 h urine protein were obviously better than those of the control group. There was no statistically significant difference in PT between the two groups of children before and after treatment. The levels of PLT and FIB in the two groups of patients after treatment were significantly lower than before treatment, and the PLT levels in the observation group were lower than those in the control group. Conclusion. The combination of Tripterygium glycosides and LMWH had good clinical effects in the treatment of children with HSPN, and it could improve the clinical symptoms, the mechanism of which might be related to the increase of PT, a decrease of PLT, and the improvement of coagulation function.

scholarly journals Clinical Study of Xingnaojing Injection Combined with Craniocerebral Hypothermia Apparatus in the Treatment of Acute Hemorrhagic Stroke

2020 ◽  
Vol 4 (2) ◽  
Author(s):  
Xianfang Yue ◽  
Hua Zhou
Keyword(s):  
Clinical Efficacy ◽  
Daily Living ◽  
Hemorrhagic Stroke ◽  
Effective Rate ◽  
Control Group ◽  
Activity Of Daily Living ◽  
Observation Group ◽  
Nihss Score ◽  
Xingnaojing Injection ◽  
Acute Hemorrhagic Stroke

Objective: To investigate the clinical effect of Xingnaojing injection combined with craniocerebral hypothermia apparatus in the treatment of acute hemorrhagic stroke. Methods: Seventy-two patients with acute hemorrhagic stroke admitted to our hospital from March 2018 to September 2019 were randomly divided into two groups, with 36 cases in each group. The control group (n=36) was treated with craniocerebral hypothermia apparatus, and the observation group (n=36) was treated with Xingnaojing injection combined with craniocerebral hypothermia apparatus. The clinical efficacy, the National Institutes of Health Stroke Scale (NIHSS) score and the activity of daily living (MBI score) after 1 month of treatment were compared. Results: The effective rate of treatment in the observation group was higher than that in the control group (P < 0.05); NIHSS score was decreased in both groups (P < 0.05); MBI score was increased in both groups, and the change range of the observation group was greater than that of the control group, showing statistically significant differences (P < 0.05). Conclusion: Xingnaojing injection combined with craniocerebral hypothermia apparatus can improve the clinical efficacy, the neurological impairment and activity of daily living in the treatment of acute hemorrhagic stroke, which is worthy of clinical application.

scholarly journals Study on the Regulation of Qinxitong Combined with Methotrexate Tablets on Multiple Inflammatory Indicators and Mechanism Factors in Rheumatoid Arthritis

2021 ◽  
Vol 5 (6) ◽  
pp. 113-117
Author(s):  
Zhaoyang Dong ◽  
Jichao Yin
Keyword(s):  
Rheumatoid Arthritis ◽  
Control Group ◽  
Study Group ◽  
Observation Group ◽  
Regulatory Effect ◽  
Inflammatory Index ◽  
Normal People ◽  
Before And After ◽  
And Control ◽  
Better Than

Objective: To study the changes of several inflammatory index mechanism factors in the clinical efficacy of tablet and methotrexate in rheumatoid arthritis. Methods: 20 patients with rheumatoid arthritis were randomly divided into observation (n =10) and control (n =10), then normal people as normal (n=10), all three groups were given methotrexate and the observation group were treated with Qin interest pain tablets. Expression of inflammatory index mechanism factors in each group. Results: After treatment, inflammatory index mechanism factors were detected; a significant decrease of IFN-g, IL-1b, IL-10, IL-37, TNF-a and other factors was found before and after combination treatment (P <0); IL-8 and IL-13 expression (P <0); the CRP, ESR score of the study group was lower than the control group (P <0.05); and the inflammatory index mechanism factors were affected by drug combination. Conclusion: Tablets combined with methotrexate in rheumatoid arthritis patients is better than methotrexate. It obviously changed the expression of the patient’s inflammatory index mechanistic factors, which has a regulatory effect on the inflammatory mechanistic factors.

scholarly journals Influence of Cinepazide Maleate on Vascular Endothelial Function of Patients with Acute Myocardial Infarction

2015 ◽  
Vol 4 (3) ◽  
pp. 1
Author(s):  
Jiaming Niu ◽  
Zhaoling Ma
Keyword(s):  
Myocardial Infarction ◽  
Acute Myocardial Infarction ◽  
Endothelial Function ◽  
Blood Serum ◽  
Control Group ◽  
Vascular Endothelial ◽  
Observation Group ◽  
Vascular Endothelial Function ◽  
Before And After ◽  
Better Than

<strong>Objective</strong>: To study influence of cinepazide maleate on vascular endothelial function of patients with acute myocardial infarction. <strong>Methods</strong>: 150 cases of patients with acute myocardial infarction were divided into the observation group and the control group, two groups were treated by conventional therapy about acute myocardial infarction, the observation group added 5%GS250 mL + cinepazide maleate 160 mg IV drip q.d, the control group added 5%GS250 mL IV drip q.d, the treatment course were 3 weeks, changes of vascular endothelial function and the blood serum no level before and after treatment were detected. <strong>Result</strong>: vascular endothelial function after treatment in observation group were obviously improved than that before treatment (<em>p</em> = 0.03) , blood serum no level was obviously increased (<em>p</em> ﹤ 0.05); about 3 weeks after treatment, vascular endothelial function in the observation group was obviously better than that of the control group (<em>p</em> = 0.04), the blood serum no level of the observation group was obviously higher than that of the control group (<em>p</em> ﹤ 0.05).<strong> Conclusion</strong>: Cinepazide maleate remarkably improves vascular endothelial function of patients with acute myocardial infarction.

scholarly journals Butyphthalide in the treatment of massive Cerebral Infarction

2019 ◽  
Vol 35 (1) ◽  
Author(s):  
Xinmin Wang ◽  
Yingjun Sun ◽  
Shugang Dong ◽  
Xiaoying Liu ◽  
Jinming Ji
Keyword(s):  
Treatment Group ◽  
Cerebral Infarction ◽  
Daily Living ◽  
Statistical Significance ◽  
Response Rates ◽  
Control Group ◽  
Activity Of Daily Living ◽  
Nihss Score ◽  
Before And After ◽  
The Difference

Objective: To evaluate the effect of butyphthalide in the treatment of massive cerebral infarction. Methods: One hundred and twenty patients with massive cerebral infarction who were admitted to the hospital between January 2017 and December 2017 were selected and divided into a treatment group (n = 60) and a control group (n = 60) using random number table, 80 each group. Patients in the control group were given conventional cerebral infarction therapy, while patients in the treatment group were given butyphthalide injection besides the conventional treatment. The National Institutes of Health Stroke Scale (NIHSS) score, score of activity of daily living (ADL), lipoprotein-associated phospholipase A2 (LP-PLA2) and prognosis were recorded and compared between the two groups. The response rates of the two groups were recorded. Results: The total response rates of the control group and treatment group were 73.85% and 93.85% respectively at the postoperative 21st day, and the difference had statistical significance (P<0.05). The NIHSS score of the two groups obviously decreased, and the ADL score significantly increased after treatment; the differences of NIHSS score and ADL score before and after treatment in the same group had statistical significance (P<0.05). The improvement of the indexes of the treatment group was obviously superior to that of the control group, and the differences between the two groups had statistical significance (P<0.05). The level of LP-PLA2 of both groups significantly decreased at the postoperative 21st day, and the difference before and after treatment in the same group was statistically significant (P<0.05); the treatment group had a significantly lower level of LP-PLA2 than the control group, and the difference had statistical significance (P<0.05). The treatment group had significantly higher positive outcome rate and lower mortality rate than the control group at the postoperative 90th day, and the differences had statistical significance (P<0.05). The incidence of adverse events of the treatment group and control group was 8.3% (5/60) and 5.0% (3/60) respectively, suggesting no significant difference (P>0.05). Conclusion: Butyphthalide has a favourable effect in treating massive cerebral infarction. It can repair neurologic impairment, improve activity of daily living, and adjust the level of LP-PLA2, suggesting favourable application values. How to cite this:Wang X, Sun Y, Dong S, Liu X, Ji J. Butyphthalide in the treatment of massive Cerebral Infarction. Pak J Med Sci. 2019;35(1):---------. doi: https://doi.org/10.12669/pjms.35.1.320 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/3.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Sign in / Sign up

Export Citation Format

Share Document